[go: up one dir, main page]

WO2001042472A3 - DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE - Google Patents

DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE Download PDF

Info

Publication number
WO2001042472A3
WO2001042472A3 PCT/US2000/042295 US0042295W WO0142472A3 WO 2001042472 A3 WO2001042472 A3 WO 2001042472A3 US 0042295 W US0042295 W US 0042295W WO 0142472 A3 WO0142472 A3 WO 0142472A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
prost
ets
novel
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/042295
Other languages
French (fr)
Other versions
WO2001042472A2 (en
Inventor
Richard Harkins
Richard J Lin
May Luke
Felipe Monteclaro
Deborah Parkes
Gordon Parry
Renate Steinbrecher
Heuit Pamela Toy Van
Jian-Ai Xuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to HK03101484.8A priority Critical patent/HK1049352A1/en
Priority to EP00992356A priority patent/EP1234037A2/en
Priority to AU43064/01A priority patent/AU4306401A/en
Priority to JP2001544345A priority patent/JP2003533177A/en
Publication of WO2001042472A2 publication Critical patent/WO2001042472A2/en
Publication of WO2001042472A3 publication Critical patent/WO2001042472A3/en
Priority to NO20022542A priority patent/NO20022542L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel transcription factor polypeptides, designated PROST-Ets, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
PCT/US2000/042295 1999-11-30 2000-11-29 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE Ceased WO2001042472A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HK03101484.8A HK1049352A1 (en) 1999-11-30 2000-11-29 Dna encoding a novel prost-ets polypeptide
EP00992356A EP1234037A2 (en) 1999-11-30 2000-11-29 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE
AU43064/01A AU4306401A (en) 1999-11-30 2000-11-29 Dna encoding a novel prost-ets polypeptide
JP2001544345A JP2003533177A (en) 1999-11-30 2000-11-29 DNA encoding novel PROST-Ets polypeptide
NO20022542A NO20022542L (en) 1999-11-30 2002-05-29 DNA encoding a new Ets polypeptide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16818299P 1999-11-30 1999-11-30
US60/168,182 1999-11-30
US71815900A 2000-11-21 2000-11-21
US09/718,159 2000-11-21

Publications (2)

Publication Number Publication Date
WO2001042472A2 WO2001042472A2 (en) 2001-06-14
WO2001042472A3 true WO2001042472A3 (en) 2002-05-10

Family

ID=26863872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042295 Ceased WO2001042472A2 (en) 1999-11-30 2000-11-29 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE

Country Status (6)

Country Link
EP (1) EP1234037A2 (en)
JP (1) JP2003533177A (en)
AU (1) AU4306401A (en)
HK (1) HK1049352A1 (en)
NO (1) NO20022542L (en)
WO (1) WO2001042472A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
WO2000070092A1 (en) 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006589A1 (en) * 1998-07-31 2000-02-10 Human Genome Sciences, Inc. Prostate derived ets factor
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2000070092A1 (en) * 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer
US6265565B1 (en) * 1998-04-03 2001-07-24 Incyte Genomics, Inc. Prostate associated Ets protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265565B1 (en) * 1998-04-03 2001-07-24 Incyte Genomics, Inc. Prostate associated Ets protein
WO2000006589A1 (en) * 1998-07-31 2000-02-10 Human Genome Sciences, Inc. Prostate derived ets factor
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2000070092A1 (en) * 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI Hinxton, UK; 14 December 1998 (1998-12-14), OETTGEN ET AL, XP002183898 *
OETTGEN ET AL: "PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 2, January 2000 (2000-01-01), pages 1216 - 1225, XP002148117 *
See also references of EP1234037A2 *
SEMENTCHENKO V I ET AL: "ETS2 FUNCTION IS REQUIRED TO MAINTAIN THE TRANSFORMED STATE OF HUMAN PROSTATE CANCER CELLS", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 17, no. 22, 1998, pages 2883 - 2888, XP000946164, ISSN: 0950-9232 *
TRAIL P A ET AL: "Monoclonal antibody drug conjugates in the treatment of cancer", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 5, 1 October 1999 (1999-10-01), pages 584 - 588, XP004257589, ISSN: 0952-7915 *
YAMADA NAOKO ET AL: "Cloning and expression of the mouse Pse gene encoding a novel Ets family member.", GENE (AMSTERDAM), vol. 241, no. 2, 11 January 2000 (2000-01-11), pages 267 - 274, XP001041527, ISSN: 0378-1119 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
HK1049352A1 (en) 2003-05-09
WO2001042472A2 (en) 2001-06-14
EP1234037A2 (en) 2002-08-28
NO20022542L (en) 2002-07-29
NO20022542D0 (en) 2002-05-29
JP2003533177A (en) 2003-11-11
AU4306401A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
WO2001038486A3 (en) Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
WO2002060932A3 (en) A serpin in bifidobacteria
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
WO2002062999A8 (en) Proteins and nucleic acids encoding same
WO2002046409A3 (en) Proteins and nucleic acids encoding same
DE69637856D1 (en) Interleukin-19.
WO2002081517A3 (en) Novel polypeptides and nucleic acids encoded thereby
WO2001044291A3 (en) Polynucleotid encoding the rg1 polypeptide
WO2000073323A3 (en) Adam polynucleotides and polypeptides
HK1049352A1 (en) Dna encoding a novel prost-ets polypeptide
WO2002012468A3 (en) 2,5-dkg permeases
HK1048495A1 (en) Dna encoding prost 07 polypeptide
WO2001081577A3 (en) Dna encoding the prost 03 polypeptide
WO2002085922A3 (en) Proteins and nucleic acids encoding same
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2000020450A3 (en) Calcium channel alpha-2/delta gene
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002081629A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003031586A3 (en) Acrp30-like polynucleotides, polypeptides, and antibodies
WO2003091402A3 (en) N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS
WO2002072770A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003072733A3 (en) Modified bace
WO2002098900A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000992356

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544345

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000992356

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000992356

Country of ref document: EP